ImageneBio, Inc. (IMA)
NASDAQ: IMA · Real-Time Price · USD
6.72
-0.11 (-1.61%)
At close: Feb 27, 2026, 4:00 PM EST
6.92
+0.20 (2.98%)
After-hours: Feb 27, 2026, 4:04 PM EST
ImageneBio Revenue
ImageneBio had revenue of $800.00K in the twelve months ending September 30, 2025. In the year 2024, ImageneBio had annual revenue of $3.50M, down -56.04%.
Revenue (ttm)
$800.00K
Revenue Growth
-56.04%
P/S Ratio
89.47
Revenue / Employee
n/a
Employees
n/a
Market Cap
71.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.50M | -4.46M | -56.04% |
| Dec 31, 2023 | 7.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIMA News
- 2 days ago - ImageneBio to Participate in Leerink Global Healthcare Conference - GlobeNewsWire
- 18 days ago - ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer - GlobeNewsWire
- 3 months ago - ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team - GlobeNewsWire
- 4 months ago - ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences - GlobeNewsWire
- 7 months ago - ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 months ago - Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million - GlobeNewsWire
- 7 months ago - Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company - GlobeNewsWire
- 8 months ago - Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals - GlobeNewsWire